T. Esaki

Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study

BackgroundVascular endothelial growth factor (VEGF)-D high have been reported as a negative prognostic marker and potential predictive marker for ramucirumab (RAM) efficacy in metastatic ...

Toshiki Masuishi ;

H. Kawakami ;

T. Tsushima ;

S. Hironaka ;

K. Muro ;

K. Shimozaki ;

H. Yasui ;

T. Esaki ;

Y. Kito ;

K. Sakai ;

K. Nishio ;

H. Shoji ;

S. Mitani ;

K. Shiraishi ;

H. Shimokawa ;

T. Tsuzuki ;

Takeshi Yamada , MD;

S. Kajiura ;

Hidehiko Hara , MD;

E. Baba ;

K. Yamazaki ;

K. Yoshimura ;

06/25/2023

First-line treatment with CET/PAN vs. BEV in elderly patients with RAS WT mCRC: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum

BackgroundElderly patients are often underrepresented in clinical trials for metastatic colorectal cancer (mCRC), and there is limited evidence on the efficacy of anti-epidermal growth fa...

H. Ojima ;

Y. Takii ;

T. Esaki ;

Yoshihisa Shimada , MD, PhD;

A. Tsuji ;

Kazuyuki Nagashima , MD;

Mariko Goto , MD, PhD;

K. Yamazaki ;

R. Sawada ;

H. Yasui ;

S. Otsu ;

K. Yamamoto ;